Implications of Complete Proteinuria Remission at any Time in Focal Segmental Glomerulosclerosis: Sparsentan DUET Trial

Quantifying the benefits of remission duration in focal and segmental glomerulosclerosis

(2022) Arenn Jauhal et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis

(2021) Lesley A. Inker et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

(2021) Brad H. Rovin et al.   KIDNEY INTERNATIONAL

Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis

(2020) Jonathan P. Troost et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Emerging drugs for treatment of focal segmental glomerulosclerosis

(2020) Howard Trachtman   EXPERT OPINION ON EMERGING DRUGS

Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

(2019) Aliza Thompson et al.   Clinical Journal of the American Society of Nephrology

GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

(2019) Lesley A. Inker et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency

(2019) Andrew S. Levey et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL

(2018) Howard Trachtman et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS

(2018) Howard Trachtman et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

(2016) Radko Komers et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

FSGS Recurrence in Adults after Renal Transplantation

(2016) Michael Rudnicki   Biomed Research International

Changing the Paradigm for the Treatment and Development of New Therapies for FSGS

(2016) Cathie Spino et al.   Frontiers in Pediatrics

Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy

(2015) A. Thompson et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Genetic dissection of kidney disorders

(2015) Friedhelm Hildebrandt   Nature Reviews Nephrology

Recurrent focal segmental glomerulosclerosis after kidney transplantation

(2015) Rebecca Trachtman et al.   PEDIATRIC NEPHROLOGY

Permeability Factors in Focal and Segmental Glomerulosclerosis

(2014) Jochen Reiser et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

Treatment of FSGS in Children

(2014) Christine B. Sethna et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome

(2014) C. E. Sadowski et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

(2013) Regina Kunz et al.   ANNALS OF INTERNAL MEDICINE

Treatment of Primary FSGS in Adults

(2012) S. M. Korbet   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Focal Segmental Glomerulosclerosis

(2011) Vivette D. D'Agati et al.   NEW ENGLAND JOURNAL OF MEDICINE